Valuation: Evotec SE

Market Cap 522M 584M 487M 442M 832M 56.46B 839M 5.85B 2.28B 28.72B 2.19B 2.14B 92.31B P/E 2026 *
-2.3x
P/E 2027 * -6.82x
Enterprise Value 664M 744M 620M 563M 1.06B 71.93B 1.07B 7.45B 2.91B 36.58B 2.79B 2.73B 118B EV / Sales 2026 *
1.11x
EV / Sales 2027 * 0.94x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-14.54%
1 week-14.54%
Current month-14.54%
1 month-14.54%
3 months-50.30%
6 months-36.55%
Current year-58.49%
1 week 3.32
Extreme 3.325
3.32
1 month 3.32
Extreme 3.325
3.32
Current year 3.32
Extreme 3.325
6.69
1 year 3.32
Extreme 3.325
8.36
3 years 3.32
Extreme 3.325
24.61
5 years 3.32
Extreme 3.325
52.21
10 years 3.32
Extreme 3.325
52.21
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 58 2019-06-18
Director/Board Member 64 2021-05-31
Director/Board Member 59 2024-06-09
Change 5-day change 1-year change 3-year change Capi.($)
-14.54%-14.54% - - 588M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.34% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
+0.50%-2.14%+331.33%+702.20% 42.84B
-0.72%-3.99%+28.50%+29.94% 42.79B
+0.34%-0.52%+6.56%+109.35% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-0.50%-3.10%-10.19%-14.35% 24.05B
-3.32%-10.86%-37.32%+316.28% 22.98B
Average -1.36%-2.37%+45.31%+156.02% 43B
Weighted average by Cap. +0.65%-1.80%+52.38%+149.38%

Financials

2026 *2027 *
Net sales 601M 673M 561M 509M 959M 65.06B 966M 6.74B 2.63B 33.09B 2.52B 2.47B 106B 724M 810M 676M 614M 1.16B 78.4B 1.16B 8.12B 3.17B 39.87B 3.04B 2.98B 128B
Net income -222M -248M -207M -188M -354M -24.03B -357M -2.49B -972M -12.22B -933M -913M -39.29B -48.25M -54M -45.02M -40.89M -77.01M -5.22B -77.58M -541M -211M -2.66B -203M -198M -8.54B
Net Debt 143M 160M 133M 121M 228M 15.47B 230M 1.6B 626M 7.87B 600M 587M 25.29B 162M 181M 151M 137M 259M 17.56B 261M 1.82B 710M 8.93B 681M 667M 28.7B
Projected Income Statement - Annual - Evotec SE
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AAA
Ratings Surperformance© - Evotec SE
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.934EUR
Average target price
4.586EUR
Spread / Average Target
+56.30%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evotec SE